Emend Injection

"A set of proteins involved in the body's natural defenses produces a large number of mutations in human DNA, according to a study led by researchers at the National Institutes of Health. The findings suggest that these naturally produced mutat"...

Emend Injection

OVERDOSE

There is no specific
information on the treatment of overdosage with fosaprepitant or aprepitant.

In the event of overdose,
fosaprepitant and/or oral aprepitant should be discontinued and general
supportive treatment and monitoring should be provided. Because of the
antiemetic activity of aprepitant, drug-induced emesis may not be effective.

Thirteen patients in the
randomized controlled trial of EMEND for Injection received both fosaprepitant
150 mg and at least one dose of oral aprepitant, 125 mg or 80 mg. Three
patients reported adverse reactions that were similar to those experienced by
the total study population.

CONTRAINDICATIONS

Hypersensitivity

EMEND for Injection is contraindicated in patients who
are hypersensitive to EMEND for Injection, aprepitant, polysorbate 80 or any
other components of the product. Known hypersensitivity reactions include:
flushing, erythema, dyspnea, and anaphylactic reactions [seeADVERSE
REACTIONS].

Concomitant Use With Pimozide Or Cisapride

Aprepitant, when administered orally, is a moderate
cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitor following the 3-day antiemetic
dosing regimen for CINV. Since fosaprepitant is rapidly converted to
aprepitant, do not use fosaprepitant concurrently with pimozide or cisapride.
Inhibition of CYP3A4 by aprepitant could result in elevated plasma
concentrations of these drugs, potentially causing serious or life-threatening
reactions [seeDRUG INTERACTIONS].

Last reviewed on RxList: 8/27/2014
This monograph has been modified to include the generic and brand name in many instances.